Skip to main content
. 2019 Apr 23;10(30):2911–2920. doi: 10.18632/oncotarget.26885

Figure 1. Assay workflow overview.

Figure 1

(A) Column-based exosomal RNA/DNA and cfDNA (exoNA) isolation from plasma of NSCLC patients. (B) Reverse transcription step. At this step, we added an exogenous RNA construct as control to monitor for PCR inhibition to each sample. (C) Pre-amplification step of exon 19, 20 and 21, in addition to QBeta and exon 7 (controls for sample inhibition and integrity, respectively). (D) Amplification Refractory Mutation System (ARMS) based quantitative PCR step.